Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Lymphoma, High-Grade Clinical Trial

Official title: Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation.

Status Recruiting

Clinical Trial Summary

Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation.

Clinical Trial Description

Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation. Aim is to find response rates and duration of combination chemotherapy (bendamustine/rituximab) in patients with relapsed or refractory CD 20 positive B cell NHL. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma, High-Grade

• NCT number: NCT00385125
• Study type: Interventional
• Source: University of Magdeburg
• Contact: Martin Mohren, PD
• Phone: 0049 231 6713266
• Email: martin.mohren@medizin.uni-magdeburg.de
• Status: Recruiting
• Phase: Phase 2
• Start date: August 2004
• Completion date: August 2010